生物学的安全性試験の世界市場 〜2022年：製品、試験タイプ (エンドドキシン試験、無菌試験、細胞株認証、バイオバーデン試験)、用途・地域別
Biologics Safety Testing Market by Product (Instruments, Services, Kits & Reagents), Test (Endotoxin, Sterility Test, Cell Line Authentication, Bioburden), Application (Vaccine Development, Blood Products, Stem Cell Research) - Global Forecast to 2022
|出版日||ページ情報||英文 142 Pages
|生物学的安全性試験の世界市場 〜2022年：製品、試験タイプ (エンドドキシン試験、無菌試験、細胞株認証、バイオバーデン試験)、用途・地域別 Biologics Safety Testing Market by Product (Instruments, Services, Kits & Reagents), Test (Endotoxin, Sterility Test, Cell Line Authentication, Bioburden), Application (Vaccine Development, Blood Products, Stem Cell Research) - Global Forecast to 2022|
|出版日: 2017年07月18日||ページ情報: 英文 142 Pages||
当レポートでは、生物学的安全性試験の世界市場を調査し、製品 & サービス・試験タイプ・用途・地域別の市場動向、市場規模・成長率の推移と今後の予測、市場促進要因ならびに市場の機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。
"The biologics safety testing market was valued at USD 2.75 billion in 2017 and expected to grow at a CAGR of 12.2% to a USD 4.90 billion market by 2022."
Growth in pharmaceutical and biotechnology industry driven by government support, the positive trend of R&D investment in the life science industry, and an increase in the number of new drug launches are factors driving the growth of this market. On the other hand, the time-consuming approval process for new drugs is considered a restraint for the market.
The biologics safety testing market is classified on the basis of product & service into kits & reagents, services, and instruments. The kits & reagents segment is expected to register highest growth rate during the forecast period. This growth can be attributed to the reoccurring purchase of kits & reagents, which is required for running tests.
The biologics safety testing market is classified by test type into endotoxin tests, sterility tests, cell line authentification and characterization tests, residual host contamination detection tests, adventitious agent detection tests, bioburden tests, and other tests. The endotoxin tests segment is expected to register the highest growth rate during the forecast period. This growth can be attributed to the increase in the number of drug launches.
By application, the biologics safety testing market is segmented into vaccine and therapeutics development; blood and blood-related products testing; cellular and gene therapy; tissue and tissue-related products testing; and stem cell research. The vaccine and therapeutics development segment are expected to register highest CAGR during the forecast period. The growth in this segment primarily attributed to initiatives for immunization and increased company investment in the development of vaccines.
Geographically, the biologics safety testing market is dominated by North America, followed by Europe. The North American region is estimated to account for the largest share of the market in 2017 and the trend is expected to continue during the forecast period. The growth in this market can be attributed to the presence of major key players in the region, a strong trend in R&D in life science industry and an increase in drug approvals.
The primary interviews conducted for this report can be categorized as follows:
Key players operating in the biologics safety testing market include Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany), SGS SA (Switzerland), WuXi Apptec (China), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Cytovance Biologics, Inc. (U.S.), Pace Analytical Services Inc. (U.S.), and Toxikon Corporation (U.S.).
The report analyses the biologics safety testing market by product & service, test type, applications, and regions. Apart from comprehensive geographic and product & service analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the report profiles companies with developments, and strategies adopted by key players to maintain and increase their shares in the market. The market research data, market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.
This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.
The report provides insights on the following strategies:
Top 25 companies analyzed for this studies are - Sartorius AG (Germany), SGS SA (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Lonza Group LTD (Switzerland), Charles River Laboratories, Inc. (U.S.), Merck KGaA (Germany), Eurofins Scientific SE (Luxembourg), Source BioScience (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Cytovance Biologics (U.S.), Toxikon Corporation (U.S.), Avance Biosciences Inc. (U.S.), Pace Analytical Services LLC. (U.S.), WuXi Apptec (China), BioMerieux SA (France), Sterigenics International LLC (U.S.), Clean Cells (France), BSL Bioservice Scientific Laboratories Munich GmbH (Germany), North American Science Associates Inc. (U.S.), PromoCell GmbH (Germany), GenScript (China), Gibraltar Laboratories (U.S.), InvivoGen (U.S.), Neopharm Labs Inc. (Canada), ViruSure GmbH (Austria)
*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.